NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call informa ...

NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company's quarterly dividend over the previous quarter's dividend. The dividend will be paid on March 15, 2024 to shareholders of record at the close of business on February 16, 2024. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutic ...

2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance rangeAnnounced transactions of $13 billion since 2020 expected to add approximately $1.2 billion to Portfolio Receipts in 2025 NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2023 outlook for Portfolio Receipts. Pablo Legorreta, Royalty Pharma's founder and Chief Exec ...

Royalty Pharma PLC (NASDAQ:RPRX) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants George Grofik - SVP & Head, IR & Communications Pablo Legorreta - Founder, Chairman & CEO Christopher Hite - Vice Chairman & EVP Terrance Coyne - EVP & CFO Marshall Urist - EVP & Head, Research & Investments Conference Call Participants Christopher Schott - JPMorgan Chase & Co. Stephen Scala - TD Cowen Andrew Baum - Citigroup Michael DiFiore - Evercore ISI Chris Shibutani - Goldman Sachs Group ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) (Exact name of registrant as specified in its charter) England and Wales 98-1535773 (State or other jurisdiction of incorporation or organization) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ ...

Royalty Pharma plc (NASDAQ:RPRX) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Pablo Legorreta - Chief Executive Officer Marshall Urist - Executive Vice President, Head of Research and Investment Terrance Coyne - Executive Vice President, Chief Financial Officer Chris Hite - Executive Vice President, Vice Chairman George Grofik - Head of Investor Relations and Communications Conference Call Participants Chris Shibutani - Goldman Sachs Hardik Parekh - JP Morgan Geoff Meacha ...

Financial Performance - Total royalty receipts for the second quarter of 2023 were $637.1 million, slightly up from $633.2 million in the same period of 2022, while total receipts for the first six months of 2023 reached $1.86 billion, compared to $1.34 billion in 2022, representing a 39% increase [148]. - Total income and other revenues for the first six months of 2023 increased by $124.2 million, or 11.3%, compared to the same period in 2022, reaching $1,222.2 million [172]. - Consolidated net income for the first six months of 2023 was $860.4 million, an increase of $240.7 million, or 38.8%, compared to the same period in 2022 [172]. - Net income attributable to Royalty Pharma plc decreased by $76.9 million, or 25.2%, in Q2 2023 compared to Q2 2022 [172]. - Income from financial royalty assets increased by $139.2 million, or 13.6%, in the first six months of 2023, driven by a $475.0 million milestone payment from Pfizer's Zavzpret [176]. Royalty Income - The cystic fibrosis franchise generated royalty receipts of $206.2 million in Q2 2023, compared to $182.0 million in Q2 2022, reflecting a growth of 13% [148]. - Royalty income from the cystic fibrosis franchise accounted for 39% of total income for Q2 2023, compared to 38% in Q2 2022 [158]. - Royalty receipts from the cystic fibrosis franchise grew by 10.1% to $422.8 million, driven by the uptake of Kaftrio and continued performance of Trikafta [236]. - Royalty receipts from Tysabri decreased by 10.7% to $170.2 million, impacted by pricing pressure and competition [236]. - Royalty receipts from Imbruvica fell by 21.4% to $131.7 million due to increased competition and market suppression [236]. Investments and Acquisitions - The company has deployed $17.0 billion to acquire royalties, milestones, and related assets on approved products since its inception in 1996, with $12.1 billion deployed from 2012 to 2022 [136]. - For development-stage product candidates, the company has invested $8.3 billion since 2012, indicating a strong commitment to funding innovation in the biopharmaceutical sector [136]. - The company invested $682.1 million in royalties, milestones, and related assets during the first six months of 2023 [205]. - In June 2023, the company acquired a royalty interest in Erleada for an upfront payment of $59 million [206]. Cash Flow and Liquidity - Cash and cash equivalents totaled $2.2 billion as of June 30, 2023, an increase from $1.7 billion as of December 31, 2022 [209]. - Net cash provided by operating activities was $1.6 billion for the first six months of 2023, compared to $1.0 billion for the same period in 2022 [208]. - Adjusted Cash Receipts for the first six months of 2023 were $1,675.6 million, up from $1,128.7 million in 2022, reflecting a significant increase in cash generation from royalty investments [226]. - Adjusted Cash Flow for the first six months of 2023 was $1,485.8 million, an increase from $848.6 million in 2022 [226]. - Current assets increased to $143.3 million as of June 30, 2023, up from $92.8 million as of December 31, 2022, indicating a significant growth in liquidity [255]. Operating Expenses - Total operating expenses for the first six months of 2023 were $494.4 million, a slight decrease of 1.2% compared to the same period in 2022 [172]. - The company recorded provision expense of $241.2 million in Q2 2023, significantly higher than the $105.7 million recorded in Q2 2022 [182]. - In the first six months of 2023, R&D funding expense decreased by $100.1 million, or 99.0%, compared to the same period in 2022, with no upfront and milestone R&D funding expense recognized in 2023 [186]. - G&A expenses increased by $29.9 million, or 29.0%, in the first six months of 2023 compared to the same period in 2022, primarily due to higher Operating and Personnel Payments [188]. Debt and Financing - The par value of total outstanding borrowings was $7.3 billion as of June 30, 2023, with $1.0 billion of senior unsecured notes maturing in September 2023 [210]. - The company’s total long-term debt as of June 30, 2023, was $6.13 billion, slightly up from $6.12 billion at the end of 2022 [241]. - The company issued $6.0 billion of senior unsecured notes in September 2020 with a weighted average coupon rate of 2.13% and annual interest payments of approximately $127.5 million [242]. - Future principal and interest payments under the notes total approximately $7.3 billion and $2.6 billion, respectively, over the next five years [251]. Strategic Initiatives - The company’s flexible business model allows it to acquire royalties across diverse therapeutic areas and treatment modalities, reducing exposure to common industry challenges [135]. - The company’s strategic alliance with MSCI Inc. aims to develop thematic life science indexes, indicating ongoing efforts to leverage capabilities for market expansion [137]. - The company’s business model relies on cash generated from existing royalties to fund investments in new royalties, highlighting its unique approach in the biopharmaceutical industry [217]. Non-GAAP Measures - Non-GAAP measures such as Adjusted Cash Receipts, Adjusted EBITDA, and Adjusted Cash Flow are critical for assessing the company's liquidity and operational performance [222]. - Adjusted EBITDA for the first six months of 2023 was $1,541.8 million, compared to $1,035.7 million in the same period of 2022 [226]. - Adjusted Cash Receipts rose by $547 million to $1.68 billion in the first half of 2023, primarily driven by a $475 million milestone payment from the FDA approval of Zavzpret [233].

Q1 2023 Financial Results Forward Looking Statements & Non-GAAP Financial Information 3 | --- | --- | --- | |-------------------|----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------| | Portfolio Update | Marshall Urist | EVP, Head of Research & Investments | | Financial Results | Terrance Coyne | EVP, Chief Financial Officer | | Conclusion | Pablo Legorreta | Founder & Chief Executiv ...

Royalty Pharma plc (NASDAQ:RPRX) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants George Grofik – Senior Vice President, Head-Investor Relations and Communications Pablo Legorreta – Founder and Chief Executive Officer Marshall Urist – Executive Vice President, Head-Research and Investments Terry Coyne – Executive Vice President and Chief Financial Officer Chris Hite – Executive Vice President and Vice Chairman Conference Call Participants Chris Shibutani – Goldman Sachs Chris Sch ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________ to __________ Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales 98-1535773 ...